

Dyspnea, Eosinopenia, Consolidation, Acidemia and Atrial Fibrillation Score and BAP-65 Score, Tools for Prediction of Mortality in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Comparative Pilot Study

Viral Sangwan, Dhruva Chaudhry, Roopa Malik¹

Departments of Pulmonary and Critical Care Medicine and ¹Obstetrics and Gynaecology, PGIMS, Rohtak, Haryana, India

Abstract

Introduction: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) being common and often fatal, prognostic tools in AECOPD are lacking. **Materials and Methods:** A prospective, observational study was carried out in fifty patients of AECOPD admitted in A and E department. Dyspnea, Eosinopenia, Consolidation, Acidemia and atrial Fibrillation (DECAF) score and elevated blood urea nitrogen, altered mental status, pulse >109, age >65 (BAP-65) score were calculated. Dyspnea was scored using extended Medical Research Council Dyspnoea score. Data were collected and analyzed using SPSS 17.0 software. **Results:** Forty-one patients were discharged and 9 (18%) died during treatment. Patients who were discharged and patients who died during hospital stay were compared. There was no significant difference in terms of sociodemographic variables, presence of comorbidities, and other markers of disease severity. A significant difference was found in blood counts, blood urea, serum creatinine, acidotic respiratory failure, and atrial fibrillation. A higher value of DECAF score and BAP-65 score was found more commonly in patients who died. Sensitivity for prediction of mortality for DECAF score and BAP-65 score was 100% and specificity was 34.1% and 63.4%, respectively. Sensitivity for prediction of need for invasive ventilation for DECAF score and BAP-65 score was 80% and 100%, respectively, and specificity was 80% and 60%, respectively. **Conclusion:** Both DECAF and BAP-65 scores were found to be good predictors of mortality and need for ventilation in this pilot study.

Keywords: Acute exacerbation chronic obstructive pulmonary disease, mortality, ventilation

INTRODUCTION

Chronic obstructive pulmonary disease (COPD)-related deaths are now the fourth leading cause of death worldwide and it will become the third leading cause of death worldwide by 2020.^[1-3] The increasing mortality has been attributed to smoking epidemic and the advanced age of world population. COPD is defined as “a chronic slowly progressive disease characterized by airflow obstruction that does not change markedly over several months.” Therefore, COPD is defined independent of exacerbations. Exacerbations are infrequent in early COPD and are largely a feature of moderate-to-severe disease.^[4] The American Thoracic Society and European Respiratory Society define COPD exacerbation as an acute change in patient’s dyspnea, cough, or sputum that is beyond normal variability and that is sufficient to warrant a change in therapy.^[5]

Despite exacerbations of COPD being both common and fatal, accurate prognostication of patients hospitalized with an exacerbation is difficult. In stable COPD, prognostic indices have been thoroughly investigated, and tools predicting mortality risk, such as BODE score, are well established.^[6] However, prognostic research in exacerbations requiring hospitalization has been limited, and there appears to be little common ground between predictors of mortality in stable disease and during acute exacerbation of COPD (AECOPD).

Address for correspondence: Dr. Viral Sangwan,
House No. 1/9J, Medical Campus, Rohtak, Haryana, India.
E-mail: drviralsangwan@yahoo.com

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Sangwan V, Chaudhry D, Malik R. Dyspnea, eosinopenia, consolidation, acidemia and atrial fibrillation score and BAP-65 score, tools for prediction of mortality in acute exacerbations of chronic obstructive pulmonary disease: A comparative pilot study. *Indian J Crit Care Med* 2017;21:671-7.

Access this article online

Quick Response Code:



Website:
www.ijccm.org

DOI:
10.4103/ijccm.IJCCM_148_17

A clinical mortality prediction tool in AECOPD could assist in decisions regarding the location of care, early escalation of care, appropriateness for end-of-life care, and suitability for early supported hospital discharge and therefore could help to reduce morbidity and mortality and direct the most efficient use of resources. In the present study, we studied and compared the recently added composite physiological score, i.e., Dyspnea, Eosinopenia, Consolidation, Acidemia and atrial Fibrillation (DECAF) score with the already existing elevated blood urea nitrogen (BUN), altered mental status, pulse >109, age >65 (BAP-65) score for prediction of mortality in patients admitted with AECOPD.

MATERIALS AND METHODS

The present prospective, observational study was carried out on fifty consecutive patients of COPD with acute exacerbation admitted in emergency department. Patients with primary diagnosis of acute exacerbation of pulmonary disease, age ≥ 35 years, and smoking history of ≥ 10 cigarette pack-years were included in the study. Patients with previous inclusion in the study, on domiciliary ventilation, comorbidity expected to limit survival to <12 months (principally metastatic malignancy), and with primary reason for admission other than AECOPD were excluded from the study. After the initial evaluation, consisting of medical history, physical examination, 12-lead electrocardiography (ECG), arterial blood gas analysis, and standard laboratory tests, all patients underwent stable-state dyspnea scoring using the extended Medical Research Council Dyspnoea (eMRCd) score, DECAF score (eMRCd Va/Vb, eosinopenia ($< 0.05 \times 10^9/L$), consolidation, academia (pH < 7.3), atrial fibrillation [AF]), and BAP-65 score (BUN > 25 , altered mental status, pulse > 109 bpm, and age > 65 years). eMRCd score subdivides patients too breathless to leave the house unaided (traditional MRCd 5) into those able independently to manage washing and/or dressing (eMRCd 5a) and those requiring assistance with both (eMRCd 5b). Details of comorbidity and maintenance medications were obtained from the patient. Presence of new consolidation on chest radiograph was recorded. Data were analyzed statistically.

Statistical tests used

Statistical testing was conducted with the Statistical Package for the Social Sciences version (SPSS, Chicago: SPSS Inc) 17.0. Continuous variables were presented as mean \pm standard deviation or median if the data were unevenly distributed. Categorical variables were expressed as frequencies and percentages. The comparison of normally distributed continuous variables between the groups was performed using Student's *t*-test. Nominal categorical data between the groups were compared using Chi-square test or Fisher's exact test as appropriate. Nonnormal distribution of continuous variables was made using Mann-Whitney U-test. A receiver operating characteristic (ROC) analysis was calculated to determine optimal cutoff value for total DECAF score and total BAP-65 score. The area under the curve, the sensitivity, and the specificity

were also calculated to analyze the diagnostic value of total DECAF score and total BAP-65 score. For all statistical tests, $P < 0.05$ was considered to indicate a significant difference.

RESULTS

A total of 63 patients of COPD were screened and fifty patients fulfilled the inclusion criteria. Out of 13 patients excluded from study, four patients were on domiciliary ventilation, one patient had metastatic malignancy, and eight patients were admitted for reason other than AECOPD. A total of fifty patients were included in the study. Out of these, 41 patients were discharged after treatment and nine patients died.

Sociodemographic data of patients are shown in Table 1. Out of the fifty patients included in the study, 43 (86%) were male. Demographic differences of variables such as age, body mass index (BMI), and sex did not have any bearing on the study outcomes. No statistical difference was found between the patients who were discharged or who died ($P > 0.05$). Both the patients who were discharged and patients who died had similar interquartile range (IQR) in terms of smoking burden in pack-years ($P = 0.835$) and duration of illness ($P = 0.502$). There was no statistically significant difference between the number of hospital admission and number of acute exacerbations in previous year in the patients who were discharged or who died.

Clinical characteristics of patients are shown in Table 2. All patients had dyspnea as the chief presenting complaint. Thirty patients also had cough with sputum as the presenting complaint. Altered sensorium was present in 11 patients, out of these two patients died. There was statistically significant difference between patients who were discharged and who died in relation to cough with sputum as the presenting complaint ($P = 0.007$).

Table 1: Sociodemographic profile of patients who survived and died during hospital stay

Variable	Survived to discharge (n=41)	Died in hospital (n=9)	P
Age (years) (mean \pm SD)	61.20 \pm 8.42	66.56 \pm 4.69	0.072
BMI	26.29 \pm 2.77	26.33 \pm 1.73	0.967
Sex (male/female)	36/5	7/2	0.595
Duration of illness (years), median (IQR)	10 (8-11)	10 (9-11)	0.502
Smoking burden (pack-years), median (IQR)	30 (20-40)	30 (22.50-40)	0.835
Quality of life			
Institutional care	0	0	-
Living independently (%)	41 (100)	8 (88.9)	0.180
Housebound (%)	18 (43.9)	3 (33.3)	0.716
Number of hospital admissions in previous year, median (IQR)	2.0 (0-2)	2.0 (0.5-2.5)	0.791
Number of acute exacerbations in previous year, median (IQR)	2.0 (0.5-2)	2.0 (1.0-2.5)	0.480

SD: Standard deviation; BMI: Body mass index; IQR: Interquartile range

Table 2: Clinical characteristics of patients who survived and died during hospital stay

	Survived to discharge (n=41)	Died in hospital (n=9)	P
Markers of disease severity (%)			
Long-term O ₂ therapy	12.2	11.1	1.000
Previous admissions requiring NIV	34.1	44.4	0.705
Cor pulmonale	29.3	2.3	0.023
Long-term prednisolone	46.3	66.7	0.463
Home-nebulized therapy	58.5	55.6	1.000
Comorbidities (%)			
Cerebrovascular disease	2.4	0	1.000
Ischemic heart disease	2.4	0	1.000
Hypertension	0	0	-
Diabetes	0	0	-
Left ventricular dysfunction	0	0	-
Chronic kidney disease	0	0	-
Presenting complaints (%)			
Dyspnea	100.0	100.0	-
Cough with sputum	51.2	100.0	0.007
Altered sensorium	22.0	22.2	1.000
Other	7.3	0	-
Examination			
Vitals (mean±SD)			
Pulse rate (bpm)	97.10±12.85	108.89±10.77	0.014
Systolic blood pressure (mmHg)	115.33±14.53	118.61±13.24	0.512
Diastolic blood pressure (mmHg)	71.66±8.39	70.42±11.37	0.757
Respiratory rate (/min)	25.41±2.29	25.56±2.40	0.869
General physical examination (%)			
Acute confusion	26.8	44.4	0.423
Pallor	0	0	-
Icterus	0	0	-
Cyanosis	4.9	11.1	0.456
Clubbing	0	11.1	0.180
Pedal edema	14.6	0	0.576
Raised JVP	12.2	0	0.570
Respiratory system examination (%)			
Rhonchi	80.5	100.0	0.423
Crepts	34.1	66.7	0.130
Other	34.1	11.1	0.387
Cardiovascular system examination (%)			
Normal	97.6	100.0	1.000
P2 loud	2.4	0.0	
Abdominal examination (%)			
Normal	97.6	100.0	1.000
Tender hepatomegaly	2.4	0.0	
Central nervous system examination (%)			

Contd...

Table 2: Contd...

	Survived to discharge (n=41)	Died in hospital (n=9)	P
Altered sensorium	7.3	11.1	0.404
Confusion	12.2	33.3	
Drowsy	2.4	0	
Normal	78.0	55.6	

NIV: Noninvasive ventilation; SD: Standard deviation; JVP: Jugular venous pulse

In our study, there was no statistically significant difference between the presence of comorbidities and presence of other markers of disease severity in the patients who were discharged or died, except for cor pulmonale which was present in significantly more number of discharged patients than died patients ($P = 0.023$). Mean pulse rate of the discharged and died patients was 97.10 ± 12.85 and 108.89 ± 10.77 , respectively ($P = 0.014$), which was statistically significant. We did not find any statistically significant difference in mean value of systolic blood pressure, diastolic blood pressure, respiratory rate, and temperature. No statistically significant difference was found between general physical examination and systemic examination of discharged and died patients in our study.

Investigations of patients are shown in Table 3. In the present study, statistically significant difference was found in the values of mean neutrophil count, lymphocyte count, eosinophil count and absolute eosinophil count, blood urea, and serum creatinine of discharged and died patients. Overall, a higher number of died patients had acidotic respiratory failure than that of discharged patients ($P = 0.007$). Consolidation on chest radiograph was seen in a significantly higher number of patients who died ($P = 0.006$). Nearly 33.3% of died patients had AF on ECG while none in the discharged group had AF.

Different types of ventilation required by patients are shown in Table 4. Out of all discharged patients, 26.8%, 65.9%, and 7.3% required invasive, noninvasive, and no ventilation for the management of AECOPD, respectively, and all died patients required invasive mechanical ventilation (IMV) ($P < 0.001$).

Various mortality-predicting scores were calculated, as shown in Table 5. On DECAF scoring, significantly higher number of patients who died ($P = 0.007$) had Grade Va eMRCD score, eosinopenia ($P < 0.001$), consolidation lung ($P = 0.007$), and AF ($P = 0.004$). Acidemia alone was not significantly associated with mortality. On statistical analysis, higher value of DECAF score was significantly found more commonly in patients who died during the study period ($P < 0.001$).

On BAP-65 scoring, all components of BAP-65 score were found more commonly associated with mortality and the difference was found to be statistically significant also.

Table 3: Investigations of chronic obstructive pulmonary disease patients who survived and died during hospital stay

Variable	Survived to discharge (n=41)	Died in hospital (n=9)	P
Biochemical parameters (mean±SD)			
Hb (g%)	12.78±2.33	13.67±1.03	0.087
TLC/mm ³	12,451.22±5207.02	13,144.44±2903.06	0.702
Neutrophils	83.56±6.15	88.78±2.54	<0.001
Lymphocytes	12.39±5.55	8.78±1.72	0.001
Monocytes	1.73±0.77	1.22±0.44	0.064
Eosinophils	1.95±0.59	1.22±0.44	0.001
Absolute eosinophil count	165±66.61	71.11±61.73	<0.001
Platelet count (lakh/mm ³)	1.63±0.59	1.35±0.33	0.184
Blood urea (mg%)	48.20±27.74	111.67±59.50	0.013
Fasting blood sugar (mg%)	94.29±17.27	89.11±15.08	0.410
Postprandial blood sugar (mg%)	140.29±22.70	147.89±21.10	0.363
Serum Na ⁺ (mEq/L)	142.34±6.04	143.00±5.98	0.768
Serum K ⁺ (mEq/l)	4.86±4.72	3.90±0.42	0.548
Serum creatinine (mg%)	0.91±0.27	2.19±1.38	0.024
Serum protein (g%)	6.66±0.64	6.91±0.29	0.076
Albumin: globulin ratio	1.14±0.15	1.16±0.14	0.796
Blood gas analysis (mean±SD)			
pH	7.26±0.08	7.18±0.03	0.007
pO ₂	47.26±17.90	51.10±13.93	0.549
pCO ₂	78.73±20.66	101.36±19.25	0.004
HCO ₃	33.67±9.30	29.61±5.14	0.214
O ₂ saturation (%)	72.83±23.76	77.72±20.12	0.569
Chest radiograph (%)			
Consolidation	34.1	88.9	0.006
Electrocardiograph (%)			
Atrial fibrillation	0	33.3	0.004

TLC: Total leukocyte count; Hb: Hemoglobin; SD: Standard deviation

Table 4: Type of ventilation required by chronic obstructive pulmonary disease patients who survived and died during hospital stay

Variable	Survived to discharge (n=41)	Died in hospital (n=9)	P
Type of ventilation (%)			
IMV	26.8	100	<0.001
NIV	65.9	0	
NO	7.3	0	

NIV: Noninvasive ventilation; IMV: Invasive mechanical ventilation; NO: No ventilation required

Statistically significant higher values of BAP-65 scores were observed in patients who died ($P < 0.001$).

In our cohort, both DECAF score and BAP-65 score performed equally well for prediction of in-hospital mortality. The AUROC for prediction of mortality [Figure 1] for DECAF score was 0.905 (95% confidence interval [CI] = 0.791–1.000) and for BAP-65 score was 0.915 (95% CI = 0.828–1.001). Sensitivity for prediction of mortality for both DECAF and BAP-65 scores was 100% and specificity was 34.1% and 63.4%, respectively. The AUROC for need for MV [Figure 2] was 0.881 (95% CI = 0.790–0.972) for DECAF score and 0.797 (95% CI = 0.665–0.928) for BAP-65 score.

DISCUSSION

AECOPD is a common cause of admission to Intensive Care Units (ICUs), but appropriate level of treatment of patients presenting to ICU with AECOPD is still debatable. Identifying upon admission those at high risk of dying in hospital could be useful for triaging patients to the appropriate level of care, determining aggressiveness of therapies, and guiding goals of care and safe discharges. There is an argument that whether ICU admission and invasive ventilation should be the default for all COPD patients presenting with acute respiratory failure or it should be offered as a last resort. Uncertainty as to whether to consider invasive ventilation in COPD patients is in part driven by an individual clinician's ability to confidently decide whether the intubation of patients with AECOPD is appropriate and which prognostic variables are predictive of poor outcome after ICU admission.^[7,8] A number of clinical variables exist that may be of prognostic significance in the management of COPD patients with acute exacerbation. Potential prognostic variables include age, smoking burden, premorbid factors, FEV₁, exercise capacity, previous ICU admissions including severe exacerbations, prior functional status, BMI, requirement for O₂ when stable, comorbidities, and various physiological and laboratory parameters and biomarkers.^[9-16] Given the systemic consequences of COPD, use of a composite index




Figure 1: Receiver operator characteristic curve for mortality




Figure 2: Receiver operator characteristic curve for need for mechanical ventilation

Table 5: Mortality-predicting scores of chronic obstructive pulmonary disease patients who survived and died during hospital stay

Variable	Survived to discharge (n=41), n (%)	Died in hospital (n=9), n (%)	P
eMRCd score			
I-IV	16 (39)	0	0.103
Va	23 (56.1)	9 (100)	
Vb	2 (4.9)	0	
DECAF score			
eMRCd Va	23 (56.1)	9 (100)	0.007
eMRCd Vb	2 (4.9)	0 (0)	1.000
Eosinopenia (<0.05 × 10 ⁹ /L)	5 (12.2)	7 (77.8)	<0.001
Consolidation	14 (34.1)	8 (89.9)	0.007
Acidemia (pH <7.3)	38 (92.7)	9 (100)	1.000
Atrial fibrillation	0	3 (33)	0.004
Median (IQR)	2.0 (1-3)	4.0 (3.5-5)	<0.001
BAP-65 score			
BUN >25	19 (46.3)	9 (100)	0.003
Altered mental status	13 (31.7)	3 (33.3)	1.000
Pulse >109 bpm	10 (24.4)	6 (66.7)	0.022
Age >65 years	11 (26.8)	7 (77.8)	0.007
Median (IQR)	1.0 (1.0-2.0)	3.0 (2.0-3.0)	<0.001

BUN: Blood urea nitrogen; eMRCd: Extended Medical Research Council Dyspnoea; DECAF: Dyspnea, Eosinopenia, Consolidation, Acidemia and atrial Fibrillation; IQR: Interquartile range; BAP-65: Elevated blood urea nitrogen, altered mental status, pulse >109, age >65

to assess prognosis may provide a more comprehensive way to evaluate COPD. Of these, clinical physiological markers, incorporated into the BODE index and other multidimensional staging tools, may be valuable in the assessment of severity and progression of disease. BODE index is the primarily established tool for prediction of mortality in stable COPD

patients.^[6] Several tools have been proposed for prediction of mortality in AECOPD such as CURB-65, BAP-65 score, and DECAF score.^[17-19] The use of CURB-65 score for assessment and guidance of therapy in patients hospitalized with AECOPD complicated with consolidation has been shown to be suboptimal.^[19] DECAF score has been added very recently to the tools but lacks external validation. According to study by Steer *et al.*, DECAF score is a stronger prognostic score than CURB-65, APACHE, or COPD and Asthma Physiological Score predictive tools.^[19] We evaluated the use of DECAF score for prediction of mortality in patients admitted to our ICU with AECOPD and also compared DECAF score with already existing BAP-65 score.

A total of 63 patients were analyzed, fifty patients fulfilled the inclusion criteria, and were analyzed in the study. Forty-one patients were discharged after treatment and 9 (18%) patients died during hospital stay. In the study by Steer *et al.* and Shorr *et al.*, mortality among patients with AECOPD was 10.4% and 4%, respectively, possibly reflecting the different threshold for hospital admission among different countries.^[17,19]

In our study, 33.3% of died patients had AF while none in the discharged group had AF. Changes in blood gases, abnormalities in pulmonary functions, and hemodynamic changes resulting from AECOPD can lead to the development of AF. AF and COPD frequently coexist and complicate treatment of both conditions. The treatment of COPD exacerbation may include beta-adrenergic agonist and theophylline, which can precipitate AF with rapid ventricular response. Pharmacologic and electrical cardioversion may be ineffective in the management of AF in patients with COPD until respiratory decompensation has been corrected, hence associated with increased mortality as is evident in our study.

Dyspnea of all patients was scored using eMRCd score. Out of the total 50 AECOPD patients studied, 32 patients had eMRCd score of Va. All died patients (9) had eMRCd score of Va. No significant relationship was found in eMRCd

scores of discharged and died patients ($P = 0.103$). Our results are contrary to those seen in study by Steer *et al.*^[19] They found a significant correlation ($P < 0.001$) between median eMRCDC scores of patients who survived and died, 4 (3–5a) and 5 (5a and b), respectively. The reason of this difference may be due to small sample size in our study and difference in perception of levels of activity causing dyspnea, therefore altering the dyspnea score.

In our study, when individual components of DECAF score were compared between survivors and died patients, statistically significant difference was found in eMRCDC Va (56.1% vs. 100%, $P = 0.007$), eosinopenia $<0.05 \times 10^9/L$ (12.2% vs. 77.8%, $P < 0.001$), consolidation (34.1% and 89.9%, $P = 0.007$), and AF (0 vs. 33.3%, $P = 0.004$). Comparison of eMRCDC Vb and acidemia pH <7.3 was not found to be significant. In our study, due to small sample size, only two patients had eMRCDC Vb score. When total DECAF score was considered, with rising DECAF score, there was rise in mortality ($P < 0.001$). Significant correlation was found on comparison of median and IQR for DECAF score between survivors and died patients (2.0 [1–3] vs. 4.0 [3.5–5.0], $P < 0.001$). The area under DECAF score (ROC curve) for prediction of mortality [Figure 1 and Table 6] was 0.905 (95% CI: 0.791–1.000), indicating good validity. The sensitivity, specificity, positive predictive value, negative predictive value, P value, and accuracy in prediction of mortality by DECAF score were 100%, 34.1%, 25%, 100%, 0.047, and 46%, respectively [Table 6].

Steer *et al.* in their study found that each individual component of DECAF score was an independent categorical predictor of mortality, eMRCDC Va (odds ratio [OR] = 5.11 [95% CI: 2.62–9.97], $P < 0.001$), eMRCDC Vb (OR = 7.30 [95% CI: 3.77–14.2], $P < 0.001$), consolidation (OR = 2.88 [95% CI: 1.69–4.90], $P < 0.001$), eosinopenia (OR = 2.76 [95% CI: 1.58–4.83], $P < 0.001$), pH (OR = 2.68 [95% CI: 1.41–5.09], $P = 0.003$), and presence of AF (OR = 2.66 [95% CI: 1.39–5.09], $P = 0.003$). The area under ROC curve for predicting in-hospital mortality was 0.86 (95% CI: 0.82–0.89), indicating good validity.^[19] In the present study, area under DECAF score (ROC curve) for prediction of need for invasive ventilation [Figure 2 and Table 7] was 0.881 (95% CI: 0.790–0.972), indicating good validity. The sensitivity, specificity, positive predictive value, negative predictive value, P value, and accuracy of DECAF score in prediction of need for invasive ventilation were 80%, 80%, 72.7%, 85.7%, <0.001 , and 80%, respectively, in our study [Table 7].

In our study, when individual components of BAP-65 score were compared between survivors and died patients, statistically significant difference was found in BUN >25 (46% vs. 100%, $P = 0.003$), pulse >109 bpm (24.4% vs. 66.7%, $P = 0.022$), and age >65 years (26.8% and 77.8%, $P = 0.007$). Comparison of altered mental status was not found to be significant. When total BAP-65 score was considered, with rising BAP-65 score, there was rise in mortality ($P < 0.001$). Significant correlation

Table 6: Results of Dyspnea, Eosinopenia, Consolidation, Acidemia and atrial Fibrillation score and elevated blood urea nitrogen, altered mental status, pulse >109 , age >65 score for prediction of mortality

	DECAF score	BAP-65 score
AUC (95% CI)	0.905 (0.791-1.000)	0.915 (0.828-1.001)
Sensitivity (%)	100	100
Specificity (%)	34.10	63.4
PPV (%)	25	37.5
NPV (%)	100	100
P	0.047	0.001
Accuracy (%)	46	50

AUC: Area under the curve; CI: Confidence interval; PPV: Positive predictive value; NPV: Negative predictive value; DECAF: Dyspnea, Eosinopenia, Consolidation, Acidemia and atrial Fibrillation; BAP-65: Elevated blood urea nitrogen, altered mental status, pulse >109 , age >65

Table 7: Results of Dyspnea, Eosinopenia, Consolidation, Acidemia and atrial Fibrillation score and elevated blood urea nitrogen, altered mental status, pulse >109 , age >65 score for prediction of need for mechanical ventilation

	DECAF score	BAP-65 score
AUC (95% CI)	0.881 (0.790-0.972)	0.797 (0.665-0.928)
Sensitivity (%)	80	100
Specificity (%)	80	60
PPV (%)	72.7	35
NPV (%)	85.7	100
P	<0.001	0.001
Accuracy (%)	80	50

AUC: Area under the curve; CI: Confidence interval; PPV: Positive predictive value; NPV: Negative predictive value; DECAF: Dyspnea, Eosinopenia, Consolidation, Acidemia and atrial Fibrillation; BAP-65: Elevated blood urea nitrogen, altered mental status, pulse >109 , age >65

was found on comparison of median and IQR for BAP-65 score between survivors and died patients (1.0 [1.0–2.0] vs. 3.0 [2.0–3.0], $P < 0.001$).

The area under BAP-65 score (ROC curve) for prediction of mortality [Figure 1 and Table 6] was 0.915 (95% CI: 0.828–1.001), indicating good validity. The sensitivity, specificity, positive predictive value, negative predictive value, P value, and accuracy in prediction of mortality by BAP-65 score were 100%, 63.4%, 37.5%, 100%, 0.001, and 50%, respectively [Table 6]. In the present study, area under BAP-65 score (ROC curve) for prediction of need for invasive ventilation [Figure 2 and Table 7] was 0.797 (95% CI: 0.665–0.928), indicating good validity. The sensitivity, specificity, positive predictive value, negative predictive value, P value, and accuracy of BAP-65 score in prediction of need for invasive ventilation were 100%, 60%, 35%, 100%, 0.001, and 50%, respectively [Table 7].

In the study by Shorr *et al.* for prediction of mortality and need for IMV, the area under the ROC curve for BAP-65 score was 0.77 (95% CI: 0.76–0.78) and 0.78 (95% CI: 0.78–0.79),

respectively. For the pooled mortality and MV need as end point, the cutoff point of class >II, >III, >IV, or V corresponded to sensitivity ranging from 0.97 to 0.12, specificity ranging from 0.18 to 0.99, a positive predictive value ranging from 0.13 to 0.64, and a negative predictive value ranging from 0.98 to 0.90, respectively.^[17]

On comparison of DECAF score and BAP-65 score for prediction of mortality and need for MV in AECOPD patients, on Pearson's correlation graph [Figure 3], we found a significant correlation ($r=0.602$, $P<0.001$). The correlation between DECAF score and BAP-65 was found to be linear. Although we had a small sample size in our study, if these two simple scores are well validated by larger studies, either of them can be used on the bed side of the patient to guide clinical care.

CONCLUSION

To conclude, a clinical prediction tool must have practicality, validity, and utility. Both scores are practical in the sense that both can be calculated easily using simple questions and routine laboratory investigations. Both DECAF and BAP-65 scores were found to be good predictors of mortality and need for IMV in the present study, in spite of small number. Larger studies are required for validation of these two simple tools to use them routinely in clinical judgment and triage of patients, i.e., to decide which patients should be given ventilator support or deferred from MV. However, individualization must be done based on clinical judgment and family goals.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.




Figure 3: Pearson's (linear correlation) graph between elevated blood urea nitrogen, altered mental status, pulse >109, age >65 score and Dyspnea, Eosinopenia, Consolidation, Acidemia and atrial Fibrillation score

REFERENCES

- World Health Organization. Available from: <http://www.who.int/rs/Respiratory/copd/burden/en/index.html>.
- Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global burden of disease study. *Lancet* 1997;349:1436-42.
- Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, *et al.* Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2007;176:532-55.
- BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. *Thorax* 1997;52 Suppl 5:S1-28.
- Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. *Eur Respir J* 2004;23:932-46.
- Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, *et al.* The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med* 2004;350:1005-12.
- Kostopoulou O, Wildman M. Sources of variability in uncertain medical decisions in the ICU: A process tracing study. *Qual Saf Health Care* 2004;13:272-80.
- Wildman MJ, O'Dea J, Kostopoulou O, Tindall M, Walia S, Khan Z, *et al.* Variation in intubation decisions for patients with chronic obstructive pulmonary disease in one critical care network. *QJM* 2003;96:583-91.
- Martínez-García MA, de la Rosa Carrillo D, Soler-Cataluña JJ, Donat-Sanz Y, Serra PC, Lerma MA, *et al.* Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013;187:823-31.
- Moreno A, Montón C, Belmonte Y, Gallego M, Pomares X, Real J, *et al.* Causes of death and risk factors for mortality in patients with severe chronic obstructive pulmonary disease. *Arch Bronconeumol* 2009;45:181-6.
- Tantucci C, Donati P, Nicosia F, Bertella E, Redolfi S, De Vecchi M, *et al.* Inspiratory capacity predicts mortality in patients with chronic obstructive pulmonary disease. *Respir Med* 2008;102:613-9.
- Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, *et al.* Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005;171:591-7.
- Slenter RH, Sprooten RT, Kotz D, Wesseling G, Wouters EF, Rohde GG, *et al.* Predictors of 1-year mortality at hospital admission for acute exacerbations of chronic obstructive pulmonary disease. *Respiration* 2013;85:15-26.
- Steer J, Norman EM, Afolabi OA, Gibson J, Bourke SC. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. *Thorax* 2012;67:117-21.
- Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, Tordera MP, Sánchez PR. Severe exacerbations and BODE index: Two independent risk factors for death in male COPD patients. *Respir Med* 2009;103:692-9.
- Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, *et al.* Pulmonary biomarkers in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006;174:6-14.
- Shorr AF, Sun X, Johannes RS, Yaitanes A, Tabak YP. Validation of a novel risk score for severity of illness in acute exacerbations of COPD. *Chest* 2011;140:1177-83.
- Shorr AF, Sun X, Johannes RS, Derby KG, Tabak YP. Predicting the need for mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease: Comparing the CURB-65 and BAP-65 scores. *J Crit Care* 2012;27:564-70.
- Steer J, Gibson J, Bourke SC. The DECAF score: Predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. *Thorax* 2012;67:970-6.